Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05320627

Enrollment

150

Registered

2022-04-11

Start date

2022-03-30

Completion date

2024-10-30

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Valvular Atrial Fibrillation

Keywords

Edoxaban, Population Pharmacokinetics, Non-Valvular Atrial Fibrillation

Brief summary

Based on the population pharmacokinetic data of Chinese patients with atrial fibrillation, the study will evaluate the suitability of the ENGAGE Population Pharmacokinetics model of edoxaban in patients with atrial fibrillation in China, and build a predictive dose model of edoxaban that meets the characteristics of Chinese people. It can provide perfect individualized dosing plan improves clinical efficacy and reduces adverse drug reactions.

Detailed description

This is an open label study. Male or female patients with non-valvular atrial fibrillation (NVAF) with age ≥20 years, and meeting the indications of edoxaban are potentially eligible for the study. Patients receive Edoxaban 15mg、30mg or 60mg according to the criteria as following: 1. Patients with severe renal insufficiency (15ml/min ≤ CrCl \<30ml/min), 15mg quaque die (QD) 2. Patients with normal or mild renal insufficiency (CrCl ≥50ml/min), 60mg QD 3. Patients with moderate renal insufficiency (30ml/min ≤ CrCl \<50ml/min), weight ≤60kg or combined use of P-gp inhibitors (such as dronedarone，ketoconazole, erythromycin, etc), 30mg QD. Patients will receive clinical evaluation at screening period, 4 weeks、8 weeks and 12 weeks after administration with Edoxaban. The following clinical evaluation items were included: body weight, vital signs (blood pressure and heart rate), CHADS2-VAS score, concomitant medication, ECG and echocardiogram, laboratory examination, safety evaluation (thromboembolic events, bleeding events, death) during treatment. Additional blood samples are collected for pharmacokinetic evaluation at screening period, pre-dose, 2±1h and 6±1h after administration at 4-, 8-, and 12-week visit, and for pharmacodynamic evaluation (FXa) at screening period, pre-dose after administration at 4-, 8-, 12-week visit. The population pharmacokinetics of Edoxaban in Chinese patients with non-valvular atrial fibrillation will be determined after 12weeks clinical observation. The ENGAGE PopPK model suitable in Chinese Patients with Non-Valvular Atrial Fibrillation will be established. Safety outcomes (thromboembolic events, bleeding events, death) will be evaluated.

Interventions

DRUGEdoxaban

Eligible patients will receive Edoxaban tablet once a day for 12 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or female NVAF patients, who need anticoagulant therapy at least 3 months 2. Age ≥20 years, 3. Creatinine clearance rate ≥ 15 ml/min 4. Sign a written informed consent form (ICF) for participating in the study 5. No simultaneous participation in any interventional study

Exclusion criteria

1. Patients with the Valve replacement 2. Patients with valvular atrial fibrillation 3. Mild and severe anemia patients 4. CrCl\<15ml/min 5. Patients on dialysis, risk of bleeding, taking antiplatelet drugs, or taking other anticoagulants 6. Contraindicated to Edoxaban. 7. Life expectancy \< 6 months. 8. Hypertension defined as systolic and/or diastolic blood pressure \> 95th age percentile or poorly controlled hypertension 9. Hepatic disease which is associated either: with coagulopathy leading to a clinically relevant bleeding risk, or alanine transaminase (ALT) \> 5x upper level of normal (ULN), or total bilirubin \> 2x ULN with direct bilirubin \> 20% of the total. 10. Active bleeding or high risk for bleeding contraindicating anticoagulant therapy. For example： * a history of intracranial, intraocular, intraspinal, retroperitoneal, or traumatic intra-articular bleeding * gastrointestinal bleeding during the prior year * peptic ulcer within the previous 90 days * surgery or injury requiring hospitalization within the previous 30 days * hemoglobin \<9 g/dl or a platelet count \<50×109/L * active bleeding at registration * any procedure associated with bleeding planned to occur during the treatment period 11. Urine pregnancy test positive if female 12. Inability to cooperate with the study procedures 13. Participation in a study with an investigational drug or medical device within 30 days prior to screening 14. Additional

Design outcomes

Primary

Measure	Time frame	Description
population pharmacokinetic evaluation	at the 4th, 8th and 12th week	Patients enrolled will be back to center for visit at scheduled timepoint. Blood sample for PopPK study was collected. Edoxaban concentrations in patient plasma will be determined, which will be analysed and compared with ENGAGE PopPK model.
pharmacokinetic evaluation	at the 4th, 8th and 12th week	Patients enrolled will be back to center for visit at scheduled timepoint. Blood for pharmacodynamic sample will be collected for Anti-FXa activity determination.

Secondary

Measure	Time frame	Description
safety evaluation	at the 4th, 8th and 12th week	Patients enrolled will be back to center for visit at scheduled timepoint. Adverse even will be recorded. The investigator will determine whether the patient is suitable to go on with the study.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORLu Hua, 1

Chinese Academy of Medical Sciences, Fuwai Hospital

PRINCIPAL_INVESTIGATORLei Tian, 2